Protein fingerprints may spot hidden transplant rejection

NCT ID NCT04851145

Completed Diagnosis Sponsor: University Hospital, Bordeaux Source: ClinicalTrials.gov ↗

First seen Jun 25, 2026 · Last updated Jun 27, 2026 · Updated 1 time

Summary

This study tested whether analyzing proteins from kidney biopsy and urine samples can improve the diagnosis of microvascular inflammation, a key sign of antibody-mediated rejection in kidney transplant recipients. Researchers used mass spectrometry to find protein signatures in 141 patients and compared results to standard diagnostic criteria. The goal is to make rejection diagnosis more consistent and accurate.

What this could mean

Our plain-language read of the trial. This is informational only — not medical advice or a prediction.

Active substance: mass spectrometry-based proteomics (protein analysis of biopsy and urine samples)
What this could lead to: If successful, this could lead to a more accurate and reliable way to diagnose antibody-mediated rejection in kidney transplants, helping doctors treat it earlier.
What could go wrong: This is a completed diagnostic study, not a treatment trial. The protein signatures may not prove accurate enough in larger, diverse groups, and the method is complex and not yet ready for routine use.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for GRAFT REJECTION are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

B cell deficiency transplant rejection

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

GRAFT REJECTION HUMORAL IMMUNITY KIDNEY TRANSPLANTATION PROTEOMICS

Contacts and locations

Locations

Hôpital Edouard Herriot

Lyon, 69003, France
Hôpital Necker

Paris, 75015, France
Hôpital Pellegrin

Bordeaux, 33000, France

More trials for these conditions

Other studies related to the condition(s) this trial covers.